Advertisement
Advertisement
CLLS
Cellectis S.A. - ADR
3.14
USDSponsored
+0.06
+1.82%
Mar 30, 11:08 UTC -4
Open
CLLS Earnings Reports
Positive Surprise Ratio
CLLS beat 15 of 22 last estimates.
68%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$13.80M
/-$0.24
Implied change from Q4 25 (Revenue/ EPS)
+13.08%
/-7.69%
Implied change from Q1 25 (Revenue/ EPS)
+14.74%
/+33.33%
Cellectis S.A. - ADR earnings per share and revenue
On Mar 19, 2026, CLLS reported earnings of -0.26 USD per share (EPS) for Q4 25, beating the estimate of -0.26 USD, resulting in a 1.78% surprise. Revenue reached 12.21 million, compared to an expected 12.81 million, with a -4.74% difference. The market reacted with a -12.37% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 13.80 million USD, implying an decrease of -7.69% EPS, and increase of 13.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Humacyte, Inc. Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.13
Surprise
+3.20%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Entera Bio Ltd. Ordinary Shares
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.07
Surprise
+23.75%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Cellectis S.A. - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Cellectis S.A. - ADR reported EPS of -$0.26, beating estimates by 1.78%, and revenue of $12.21M, -4.74% below expectations.
How did the market react to Cellectis S.A. - ADR's Q4 2025 earnings?
The stock price moved down -12.37%, changed from $3.80 before the earnings release to $3.33 the day after.
When is Cellectis S.A. - ADR expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Cellectis S.A. - ADR's next earnings report?
Based on 6
analysts, Cellectis S.A. - ADR is expected to report EPS of -$0.24 and revenue of $13.80M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement